Rivaroxaban 20 MG + Warfarin
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nonvalvular Atrial Fibrillation
Conditions
Nonvalvular Atrial Fibrillation
Trial Timeline
Feb 13, 2020 → Feb 1, 2023
NCT ID
NCT04073316About Rivaroxaban 20 MG + Warfarin
Rivaroxaban 20 MG + Warfarin is a approved stage product being developed by Bayer for Nonvalvular Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT04073316. Target conditions include Nonvalvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04073316 | Approved | UNKNOWN |
Competing Products
6 competing products in Nonvalvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837 | AstraZeneca | Phase 2 | 52 |
| AZD0837 + VKA INR 2-3 | AstraZeneca | Phase 2 | 52 |
| Certoparin | Novartis | Phase 3 | 77 |
| Eliquis | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Pre-clinical | 20 |